Alice Pébay

Alice Pébay

Auto-generated profile, based on publicly available information

Alice Pébay

Department of Anatomy and Physiology, The University of Melbourne, Parkville, Australia

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
XHXavier Hadoux
Xavier Hadoux
FHFlora Hui
Flora Hui
JLJeremiah K. H. Lim
Jeremiah K. H. Lim
CMColin L. Masters
Colin L. Masters
APAlice Pébay
Alice Pébay
PWPeter van Wijngaarden
Peter van Wijngaarden
Studies of rodent models of Alzheimer’s disease (AD) and of human tissues suggest that the retinal changes that occur in AD, including the accumulation of amyloid beta (Aβ), may serve as surrogate markers of brain Aβ levels. As Aβ has a wavelength-dependent effect on light scatter, we investigate the potential for in vivo retinal hyperspectral imaging to serve as a biomarker of brain Aβ. Significant differences in the retinal reflectance spectra are found between individuals with high Aβ burden on brain PET imaging and mild cognitive impairment (n = 15), and age-matched PET-negative controls (n = 20). Retinal imaging scores are correlated with brain Aβ loads. The findings are validated in an independent cohort, using a second hyperspectral camera. A similar spectral difference is found between control and 5xFAD transgenic mice that accumulate Aβ in the brain and retina. These findings indicate that retinal hyperspectral imaging may predict brain Aβ load.

1 October 2019 in Stem Cell Reports
Verified
Journal Article
Open access
HKHenna Konttinen
Henna Konttinen
MCMauricio Castro Cabral-da-Silva
Mauricio Castro Cabral-da-Silva
SOSohvi Ohtonen
Sohvi Ohtonen
SWSara Wojciechowski
Sara Wojciechowski
ASAnastasia Shakirzyanova
Anastasia Shakirzyanova
TMTarja Malm
Tarja Malm
Here we elucidate the effect of Alzheimer disease (AD)-predisposing genetic backgrounds, APOE4, PSEN1ΔE9, and APPswe, on functionality of human microglia-like cells (iMGLs). We present a physiologically relevant high-yield protocol for producing iMGLs from induced pluripotent stem cells. Differentiation is directed with small molecules through primitive erythromyeloid progenitors to re-create microglial ontogeny from yolk sac. The iMGLs express microglial signature genes and respond to ADP with intracellular Ca2+ release distinguishing them from macrophages. Using 16 iPSC lines from healthy donors, AD patients and isogenic controls, we reveal that the APOE4 genotype has a profound impact on several aspects of microglial functionality, whereas PSEN1ΔE9 and APPswe mutations trigger minor alterations. The APOE4 genotype impairs phagocytosis, migration, and metabolic activity of iMGLs but exacerbates their cytokine secretion. This indicates that APOE4 iMGLs are fundamentally unable to mount normal microglial functionality in AD.

1 July 2016 in Resuscitation
Verified
Journal Article
Closed access
GEGlenn M. Eastwood
Glenn M. Eastwood
ASAntoine G. Schneider
Antoine G. Schneider
SSSatoshi Suzuki
Satoshi Suzuki
LPLeah Peck
Leah Peck
HYHelen Young
Helen Young
RBRinaldo Bellomo
Rinaldo Bellomo

15 June 2022 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
HJHenna Jäntti
Henna Jäntti
VSValeriia Sitnikova
Valeriia Sitnikova
YIYevheniia Ishchenko
Yevheniia Ishchenko
ASAnastasia Shakirzyanova
Anastasia Shakirzyanova
LGLuca Giudice
Luca Giudice
TMTarja Malm
Tarja Malm
Background: Microglia are the endogenous immune cells of the brain and act as sensors of pathology to maintain brain homeostasis and eliminate potential threats. In Alzheimer's disease (AD), toxic amyloid beta (Aβ) accumulates in the brain and forms stiff plaques. In late-onset AD accounting for 95% of all cases, this is thought to be due to reduced clearance of Aβ. Human genome-wide association studies and animal models suggest that reduced clearance results from aberrant function of microglia. While the impact of neurochemical pathways on microglia had been broadly studied, mechanical receptors regulating microglial functions remain largely unexplored. Methods: Here we showed that a mechanotransduction ion channel, PIEZO1, is expressed and functional in human and mouse microglia. We used a small molecule agonist, Yoda1, to study how activation of PIEZO1 affects AD-related functions in human induced pluripotent stem cell (iPSC)-derived microglia-like cells (iMGL) under controlled laboratory experiments. Cell survival, metabolism, phagocytosis and lysosomal activity were assessed using real-time functional assays. To evaluate the effect of activation of PIEZO1 in vivo, 5-month-old 5xFAD male mice were infused daily with Yoda1 for two weeks through intracranial cannulas. Microglial Iba1 expression and Aβ pathology were quantified with immunohistochemistry and confocal microscopy. Published human and mouse AD datasets were used for in-depth analysis of PIEZO1 gene expression and related pathways in microglial subpopulations. Results: We show that PIEZO1 orchestrates Aβ clearance by enhancing microglial survival, phagocytosis, and lysosomal activity. Aβ inhibited PIEZO1-mediated calcium transients, whereas activation of PIEZO1 with a selective agonist, Yoda1, improved microglial phagocytosis resulting in Aβ clearance both in human and mouse models of AD. Moreover, PIEZO1 expression was associated with a unique microglial transcriptional phenotype in AD as indicated by assessment of cellular metabolism, and human and mouse single-cell datasets. Conclusion: These results indicate that the compromised function of microglia in AD could be improved by controlled activation of PIEZO1 channels resulting in alleviated Aβ burden. Pharmacological regulation of these mechanoreceptors in microglia could represent a novel therapeutic paradigm for AD.

1 November 2005 in Stem Cells
Verified
Journal Article
Closed access
PDF file
APAlice Pébay
Alice Pébay
Raymond C. B. WongRaymond C. B. Wong
Raymond C. B. Wong
Stuart PitsonStuart Pitson
Stuart Pitson
Ernst WolvetangErnst Wolvetang
Ernst Wolvetang
Gary PehGary Peh
Gary Peh
MPMartin F. Pera
Martin F. Pera
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.

1 June 2016 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
SHSandy S. C. Hung
Sandy S. C. Hung
VCVicki Chrysostomou
Vicki Chrysostomou
FLFan Li
Fan Li
JLJeremiah K. H. Lim
Jeremiah K. H. Lim
JWJiang-Hui Wang
Jiang-Hui Wang
AHAlex Hewitt
Alex Hewitt
Purpose: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein (Cas) has recently been adapted to enable efficient editing of the mammalian genome, opening novel avenues for therapeutic intervention of inherited diseases. In seeking to disrupt yellow fluorescent protein (YFP) in a Thy1-YFP transgenic mouse, we assessed the feasibility of utilizing the adeno-associated virus 2 (AAV2) to deliver CRISPR/Cas for gene modification of retinal cells in vivo. Methods: Single guide RNA (sgRNA) plasmids were designed to target YFP, and after in vitro validation, selected guides were cloned into a dual AAV system. One AAV2 construct was used to deliver Streptococcus pyogenes Cas9 (SpCas9), and the other delivered sgRNA against YFP or LacZ (control) in the presence of mCherry. Five weeks after intravitreal injection, retinal function was determined using electroretinography, and CRISPR/Cas-mediated gene modifications were quantified in retinal flat mounts. Results: Adeno-associated virus 2–mediated in vivo delivery of SpCas9 with sgRNA targeting YFP significantly reduced the number of YFP fluorescent cells of the inner retina of our transgenic mouse model. Overall, we found an 84.0% (95% confidence interval [CI]: 81.8–86.9) reduction of YFP-positive cells in YFP-sgRNA–infected retinal cells compared to eyes treated with LacZ-sgRNA. Electroretinography profiling found no significant alteration in retinal function following AAV2-mediated delivery of CRISPR/Cas components compared to contralateral untreated eyes. Conclusions: Thy1-YFP transgenic mice were used as a rapid quantifiable means to assess the efficacy of CRISPR/Cas-based retinal gene modification in vivo. We demonstrate that genomic modification of cells in the adult retina can be readily achieved by viral-mediated delivery of CRISPR/Cas.